Frontiers in Physiology (Jul 2021)
The Composite of 3, 4-Dihydroxyl-Phenyl Lactic Acid and Notoginsenoside R1 Attenuates Myocardial Ischemia and Reperfusion Injury Through Regulating Mitochondrial Respiratory Chain
- Li Yan,
- Li Yan,
- Li Yan,
- Li Yan,
- Chun-Shui Pan,
- Chun-Shui Pan,
- Chun-Shui Pan,
- Chun-Shui Pan,
- Yu-Ying Liu,
- Yu-Ying Liu,
- Yu-Ying Liu,
- Yu-Ying Liu,
- Yuan-Chen Cui,
- Yuan-Chen Cui,
- Yuan-Chen Cui,
- Yuan-Chen Cui,
- Bai-He Hu,
- Bai-He Hu,
- Bai-He Hu,
- Bai-He Hu,
- Xin Chang,
- Xin Chang,
- Xin Chang,
- Xin Chang,
- Xiao-Hong Wei,
- Xiao-Hong Wei,
- Xiao-Hong Wei,
- Xiao-Hong Wei,
- Ping Huang,
- Ping Huang,
- Ping Huang,
- Ping Huang,
- Jian Liu,
- Jian Liu,
- Jian Liu,
- Jian Liu,
- Jian Liu,
- Jing-Yu Fan,
- Jing-Yu Fan,
- Jing-Yu Fan,
- Jing-Yu Fan,
- Quan Li,
- Quan Li,
- Quan Li,
- Quan Li,
- Kai Sun,
- Kai Sun,
- Kai Sun,
- Kai Sun,
- Lu-Lu Yan,
- Lu-Lu Yan,
- Lu-Lu Yan,
- Lu-Lu Yan,
- Ke He,
- Ke He,
- Ke He,
- Ke He,
- Jing-Yan Han,
- Jing-Yan Han,
- Jing-Yan Han,
- Jing-Yan Han,
- Jing-Yan Han
Affiliations
- Li Yan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China
- Li Yan
- Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People’s Republic of China, Beijing, China
- Li Yan
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
- Li Yan
- Beijing Microvascular Institute of Intergration of Chinese and Western Medicine, Beijing, China
- Chun-Shui Pan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China
- Chun-Shui Pan
- Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People’s Republic of China, Beijing, China
- Chun-Shui Pan
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
- Chun-Shui Pan
- Beijing Microvascular Institute of Intergration of Chinese and Western Medicine, Beijing, China
- Yu-Ying Liu
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China
- Yu-Ying Liu
- Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People’s Republic of China, Beijing, China
- Yu-Ying Liu
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
- Yu-Ying Liu
- Beijing Microvascular Institute of Intergration of Chinese and Western Medicine, Beijing, China
- Yuan-Chen Cui
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China
- Yuan-Chen Cui
- Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People’s Republic of China, Beijing, China
- Yuan-Chen Cui
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
- Yuan-Chen Cui
- Beijing Microvascular Institute of Intergration of Chinese and Western Medicine, Beijing, China
- Bai-He Hu
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China
- Bai-He Hu
- Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People’s Republic of China, Beijing, China
- Bai-He Hu
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
- Bai-He Hu
- Beijing Microvascular Institute of Intergration of Chinese and Western Medicine, Beijing, China
- Xin Chang
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China
- Xin Chang
- Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People’s Republic of China, Beijing, China
- Xin Chang
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
- Xin Chang
- Beijing Microvascular Institute of Intergration of Chinese and Western Medicine, Beijing, China
- Xiao-Hong Wei
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China
- Xiao-Hong Wei
- Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People’s Republic of China, Beijing, China
- Xiao-Hong Wei
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
- Xiao-Hong Wei
- Beijing Microvascular Institute of Intergration of Chinese and Western Medicine, Beijing, China
- Ping Huang
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China
- Ping Huang
- Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People’s Republic of China, Beijing, China
- Ping Huang
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
- Ping Huang
- Beijing Microvascular Institute of Intergration of Chinese and Western Medicine, Beijing, China
- Jian Liu
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China
- Jian Liu
- Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China
- Jian Liu
- Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People’s Republic of China, Beijing, China
- Jian Liu
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
- Jian Liu
- Beijing Microvascular Institute of Intergration of Chinese and Western Medicine, Beijing, China
- Jing-Yu Fan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China
- Jing-Yu Fan
- Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People’s Republic of China, Beijing, China
- Jing-Yu Fan
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
- Jing-Yu Fan
- Beijing Microvascular Institute of Intergration of Chinese and Western Medicine, Beijing, China
- Quan Li
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China
- Quan Li
- Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People’s Republic of China, Beijing, China
- Quan Li
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
- Quan Li
- Beijing Microvascular Institute of Intergration of Chinese and Western Medicine, Beijing, China
- Kai Sun
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China
- Kai Sun
- Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People’s Republic of China, Beijing, China
- Kai Sun
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
- Kai Sun
- Beijing Microvascular Institute of Intergration of Chinese and Western Medicine, Beijing, China
- Lu-Lu Yan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China
- Lu-Lu Yan
- Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People’s Republic of China, Beijing, China
- Lu-Lu Yan
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
- Lu-Lu Yan
- Beijing Microvascular Institute of Intergration of Chinese and Western Medicine, Beijing, China
- Ke He
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China
- Ke He
- Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People’s Republic of China, Beijing, China
- Ke He
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
- Ke He
- Beijing Microvascular Institute of Intergration of Chinese and Western Medicine, Beijing, China
- Jing-Yan Han
- Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China
- Jing-Yan Han
- Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China
- Jing-Yan Han
- Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People’s Republic of China, Beijing, China
- Jing-Yan Han
- State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China
- Jing-Yan Han
- Beijing Microvascular Institute of Intergration of Chinese and Western Medicine, Beijing, China
- DOI
- https://doi.org/10.3389/fphys.2021.538962
- Journal volume & issue
-
Vol. 12
Abstract
Aim3,4-Dihydroxyl-phenyl lactic acid (DLA) and notoginsenoside R1 (R1) are known to protect ischemia and reperfusion (I/R) injury by targeting Sirtuin1/NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 10/the Mitochondrial Complex I (Sirt-1/NDUFA10/Complex I) and Rho-associated kinase/adenosine triphosphate (ROCK/ATP) ATP synthase δ subunit (ATP 5D), respectively. We hypothesized that a composite of the two may exhibit a more potent effect on I/R injury. The study was designed to test this hypothesis.Materials and MethodsMale Sprague–Dawley rats underwent left anterior descending artery occlusion and reperfusion, with or without DLA, R1, or a combination of 3,4-dihydroxyl-phenyl lactic acid and notoginsenoside R1 (DR) pretreatment. Heart function, myocardial morphology, myocardial infarct, myocardial blood flow (MBF), apoptosis, vascular diameter, and red blood cell (RBC) velocity in venules were evaluated. Myeloperoxidase (MPO), malondialdehyde (MDA), and 8-oxo-deoxyguanosine (8-OHdG) were assessed. The content of ATP, adenosine diphosphate (ADP), and adenosine monophosphate (AMP), the activity of mitochondrial respiratory chain Complex I and its subunit NDUFA10, the Mitochondrial Complex V (Complex V) and its subunit ATP 5D, Sirt-1, Ras homolog gene family, member A (RhoA), ROCK-1, and phosphorylated myosin light chain (P-MLC) were evaluated. R1 binding to Sirt-1 was determined by surface plasmon resonance.ResultsDLA inhibited the expression of Sirt-1, the reduction in Complex I activity and its subunit NDUFA10 expression, the increase in MPO, MDA, and 8-OhdG, and apoptosis. R1 inhibited the increase in the expression of RhoA/ROCK-1/P-MLC, the reduction of Complex V activity and its subunit ATP 5D expression, alleviated F-actin, and myocardial fiber rupture. Both DLA and R1 reduced the myocardial infarction size, increased the velocities of RBC in venules, and improved MBF and heart function impaired by I/R. DR exhibited effects similar to what was exerted, respectively, by DLA and R1 in terms of respiratory chain complexes and related signaling and outcomes, and an even more potent effect on myocardial infarct size, RBC velocity, heart function, and MBF than DLA and R1 alone.ConclusionA combination of 3,4-dihydroxyl-phenyl lactic acid and notoginsenoside R1 revealed a more potent effect on I/R injury via the additive effect of DLA and R1, which inhibited not only apoptosis caused by low expression of Sirt-1/NDUFA10/Complex I but also myocardial fiber fracture caused by RhoA/ROCK-1 activation and decreased expression of ATP/ATP 5D/Complex V.
Keywords
- 3
- 4-dihydroxyl-phenyl lactic acid
- notoginsenoside R1
- myocardium ischemia reperfusion injury
- Complex I
- Complex V